Instruction for use: Nabumetone e (Nabumetone um)

Pharmacological group

Other non-narcotic analgesics, including non-steroidal and other anti-inflammatory drugs

Nosological classification (ICD-10)

M06.9 Other specified rheumatoid arthritis

Rheumatoid arthritis,Pain syndrome in rheumatic diseases, Pain in rheumatoid arthritis, Inflammation in rheumatoid arthritis, Degenerative forms of rheumatoid arthritis, Children's rheumatoid arthritis, Exacerbation of rheumatoid arthritis, Acute articular rheumatism, Rheumatic arthritis, Rheumatic polyarthritis, Rheumatoid arthritis, Rheumatic polyarthritis, Rheumatoid arthritis, Rheumatoid arthritis of active course, Rheumatoid arthritis, Rheumatoid polyarthritis, Acute rheumatoid arthritis, Acute rheumatism

M10 Gout

Exacerbation of gout, Acute articular attack with gout, Acute gouty attack, Gouty attack, Recurrent gout attacks, Chronic gout

M13.9 Arthritis, unspecified

Arthritis,Purulent arthritis (non-infectious), acute Arthritis,Pain in acute inflammatory diseases of the musculoskeletal system,Pain in chronic inflammatory diseases of the musculoskeletal system,The pain in osteoarthritis, Inflammation in osteoarthritis, Inflammatory arthropathy, Inflammatory and degenerative joint diseases, Inflammatory disease of the musculoskeletal system, Inflammatory joint disease, Inflammatory diseases of the musculoskeletal system, destructive arthritis, The disease of the musculoskeletal system, Diseases of the musculoskeletal system, Diseases of the musculoskeletal system and connective tissue, Infections musculoskeletal system, monoartrit, Non-infectious arthritis, rheumatic arthritis, Osteoarthritis, Acute inflammation of the musculoskeletal tissue, Acute inflammatory diseases of the musculoskeletal system, Acute inflammatory condition of the musculoskeletal system, Acute arthritis, Acute osteoarthritis, Post-traumatic osteoarthritis, Reactive arthritis, Chronic inflammatory diseases of the joints, Chronic arthritis, Chronic inflammatory arthritis, Chronic inflammation of the inner layer of the joint capsule, Chronic inflammation of the joint capsule,Chronic inflammatory disease of the joints, Exudative arthritis

M15-M19 Osteoarthritis

Code CAS 42924-53-8

Characteristics of Nabumetone

White or colorless crystalline powder. Almost nerastvorim in the water. Soluble in alcohol and most organic solvents.

Pharmacology

Pharmacological action - anti-inflammatory, antipyretic, analgesic.

The mechanism of action is associated with the blockade of cyclooxygenase, which leads to a disruption of the metabolism of arachidonic acid and a decrease in the concentration of PG, thromboxanes. It suppresses exudative and proliferative processes in the inflammatory focus, reduces the concentration of bradykinin and histamine, and also increases the sensitivity threshold of pain receptors. Hypothermic effect is due to a decrease in the concentration of pyrogens in the cerebrospinal fluid and the hypothalamic zone, an increase in heat transfer (no effect on heat production).

After oral administration, it is quickly and completely absorbed. Bioavailability is about 80%. Biotransformed with the formation of an active metabolite (35% of the dose) - 6-methoxy-2-naphthylacetic acid (6-MNA) and 50% of unidentified metabolites. 6-MNA binds to blood proteins by 99%, undergoes terminal transformations in the liver (inactivation). T1 / 2 - 24 hours 75% of the accepted dose is excreted by the kidneys within 48 hours.

Application of Nabumetone

Osteoarthritis, rheumatoid arthritis.

Contraindications

Hypersensitivity, peptic ulcer of the stomach and duodenum, bronchial asthma, polyposis of the nose, heart failure, peripheral edema, hepatic-renal insufficiency, hemophilia, hypocoagulation states.

Restrictions for use

There is no information on the safety of use in pregnant and lactating women, as well as in children.

pregnancy and lactation

The action category for fetus by FDA is C.

Side effects of Nabumetone

Dyspepsia, NSAID-gastropathy, nausea, vomiting, heartburn, diarrhea, abdominal pain, ulceration of the gastrointestinal tract, gastrointestinal bleeding, bronchospasm, cardiac failure, vasculitis, arrhythmia, arterial hypertension, edema, kidney damage, dizziness, headache, sweating, insomnia, drowsiness, tinnitus, dysuria, hematuria, crystalluria, albuminuria, agranulocytosis, leukopenia, thrombocytopenia, anemia, allergic reactions.

Interaction

Increases the activity of anticoagulants, antiaggregants and fibrinolytics, as well as side effects of glucocorticoids, oral contraceptives. Antacids and colestramine slow the absorption from the digestive tract.

Routes of administration

Inside.